Eagle Pharmaceuticals Stock Forecast, Price & News

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

Is Eagle Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Eagle Pharmaceuticals stock.
View analyst ratings for Eagle Pharmaceuticals or view top-rated stocks.

How has Eagle Pharmaceuticals' stock price been impacted by COVID-19?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EGRX stock has increased by 21.4% and is now trading at $47.42.
View which stocks have been most impacted by COVID-19.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Eagle Pharmaceuticals.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share for the quarter, topping the consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to analyst estimates of $46.70 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 2.97% and a net margin of 3.14%. During the same quarter in the prior year, the firm posted $0.51 earnings per share.
View Eagle Pharmaceuticals' earnings history.

What price target have analysts set for EGRX?

2 brokerages have issued 12 month target prices for Eagle Pharmaceuticals' stock. Their forecasts range from $51.00 to $51.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $51.00 in the next year. This suggests a possible upside of 7.5% from the stock's current price.
View analysts' price targets for Eagle Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:

• Scott L. Tarriff, President, Chief Executive Officer & Director
• Michael Moran, Executive VP, Chief Operating & Commercial Officer
• Brian Cahill, Chief Financial Officer
• Judith Ng-Cashin, Chief Medical Officer & Executive Vice President
• Daniel O'Connor, Chief Strategy Officer

Who are some of Eagle Pharmaceuticals' key competitors?

Some companies that are related to Eagle Pharmaceuticals include ChemoCentryx (CCXI), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Emergent BioSolutions (EBS), TG Therapeutics (TGTX), Sage Therapeutics (SAGE), Prothena (PRTA), Lyell Immunopharma (LYEL), Harmony Biosciences (HRMY), Xencor (XNCR), Indivior (INVVY), Taro Pharmaceutical Industries (TARO), Nektar Therapeutics (NKTR), Nuvation Bio (NUVB) and Trillium Therapeutics (TRIL).
View all of EGRX's competitors.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Radius Health (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (15.62%), Janus Henderson Group PLC (11.83%), Dimensional Fund Advisors LP (2.17%), Smith Graham & Co. Investment Advisors LP (1.95%), Geode Capital Management LLC (1.62%) and Renaissance Technologies LLC (1.54%).
View institutional ownership trends for Eagle Pharmaceuticals.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Goldman Sachs Group Inc., Millennium Management LLC, BlackRock Inc., Russell Investments Group Ltd., Two Sigma Advisers LP, Smith Graham & Co. Investment Advisors LP, and Citigroup Inc..
View insider buying and selling activity for Eagle Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Balyasny Asset Management LLC, South Dakota Investment Council, Assenagon Asset Management S.A., Summit Global Investments, Krensavage Asset Management LLC, Tri Locum Partners LP, and SummerHaven Investment Management LLC.
View insider buying and selling activity for Eagle Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $47.42.

How much money does Eagle Pharmaceuticals make?

Eagle Pharmaceuticals has a market capitalization of $612.19 million and generates $187.80 million in revenue each year. The specialty pharmaceutical company earns $11.99 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Eagle Pharmaceuticals have?

Eagle Pharmaceuticals employs 106 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is www.eagleus.com.

Where are Eagle Pharmaceuticals' headquarters?

Eagle Pharmaceuticals is headquartered at 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at (201) 326-5300 or via email at [email protected].